As a professional biotechnology company, Diagreat always adheres to the philosophy of “Innovation, Pragmatism and Win-Win”, and is committed to developing more leading medical technologies to bring more benefits to patients worldwide. At the conference, Diagreat will share its latest achievements in drug concentration detection technology, which will address the clinical pain point of not being able to detect chemical drugs and biologics on the same platform.
The chemiluminescence platform utilizes SDC directed coupling technology to achieve stable results and small batch-to-batch variation, providing a more efficient and accurate means of detection for clinical use.
Diagreat's development plan is equally impressive. It is expected that in the next 2-3 years, we will market 36 small molecules, 14 large molecules and more than 50 routine items, and ultimately realize more than a hundred chemiluminescent solutions. This ambitious goal will give a strong boost to China's drug R&D endeavors and bring more hope to patients around the world.
